Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, which covers methods of using LP-284 to treat mantle cell lymphoma (MCL), double-hit lymphoma (DHL), and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. This development matters because, once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern's existing composition-of-matter patent estate. For patients and investors, this means a longer period of market exclusivity for a promising therapy in areas of high unmet need.
LP-284 is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors. The drug was developed through the company's RADR® artificial intelligence platform, which integrates large-scale genomic and biological data with advanced machine learning to identify patients most likely to benefit from Lantern's therapies. LP-284 has already received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. These designations provide incentives such as tax credits and market exclusivity, further underscoring the therapy's potential.
The patent allowance is a significant milestone for Lantern Pharma, as it strengthens the intellectual property surrounding LP-284 and could enhance the company's ability to attract partnerships or investment. For the broader oncology field, it signals continued progress in leveraging AI to accelerate drug development and precision medicine. As the company advances its pipeline, which also includes LP-184 (zirdafulven), LP-300, along with its central-nervous-system-focused subsidiary Starlight Therapeutics and its AI subsidiary Open-Medicine AI, the expansion of patent protection could provide a competitive edge in the crowded blood cancer space.
Readers should note that while patent allowances are a positive step, they do not guarantee clinical success or regulatory approval. The ongoing Phase 1a trial will provide critical data on safety and efficacy. For those tracking Lantern Pharma, further updates can be found in the company's newsroom at https://ibn.fm/LTRN. The full press release is available at https://ibn.fm/5zEya. Additional information about MissionIR, which distributes such announcements, can be found at MissionIR, and its parent network at IBN. The news was also syndicated through InvestorWire and shared across social media distribution channels, reflecting the wide reach of corporate communications solutions.
In summary, this patent allowance represents a strategic win for Lantern Pharma, potentially extending LP-284's commercial life and reinforcing the value of AI-driven drug discovery in oncology. Stakeholders in the health and biotech sectors should monitor the company's clinical progress and regulatory milestones as they unfold.
